Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · Real-Time Price · USD

547.03

-0.86 (-0.16%)

At close: Nov 11, 2026, 4:00 PM EST

542.94

-4.09 (-0.75%)

After-hours: Nov 11, 2026, 7:51 PM EST

Vertex Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	138,693	115,026	103,707	104,849	74,127	55,834
Market Cap Growth	33.50%	10.91%	-1.09%	41.44%	32.76%	-9.15%
Enterprise Value	135,350	104,851	94,253	91,965	65,181	49,750
Last Close Price	547.03	453.36	402.70	406.89	288.78	219.60

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	35.18	29.10	-	28.97	22.31	23.84
Forward PE	28.99	22.61	22.66	24.44	18.83	16.42
PS Ratio	10.71	9.58	9.41	10.62	8.30	7.37
PB Ratio	6.63	6.16	6.32	5.96	5.33	5.53
P/TBV Ratio	13.92	6.71	7.15	6.70	6.07	6.42
P/FCF Ratio	43.31	36.02	-	31.42	18.89	23.18
P/OCF Ratio	37.54	31.68	-	29.64	17.95	21.12
PEG Ratio	2.37	0.15	1.21	1.92	0.58	1.62

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	10.45	8.74	8.55	9.32	7.30	6.57
EV/EBITDA Ratio	26.54	21.55	20.59	20.54	14.40	12.38
EV/EBIT Ratio	27.65	22.37	21.45	21.35	14.89	12.78
EV/FCF Ratio	42.27	32.83	-	27.56	16.61	20.66

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.31	0.11	0.11	0.05	0.07	0.10
Debt / EBITDA Ratio	1.20	0.40	0.37	0.18	0.20	0.24
Debt / FCF Ratio	2.02	0.64	-	0.24	0.23	0.40
Net Debt / Equity Ratio	-0.16	-0.55	-0.58	-0.73	-0.72	-0.65
Net Debt / EBITDA Ratio	-0.65	-2.11	-2.07	-2.88	-2.21	-1.63
Net Debt / FCF Ratio	-1.04	-3.22	11.99	-3.87	-2.54	-2.72
Asset Turnover	0.45	0.50	0.49	0.48	0.57	0.60
Inventory Turnover	3.02	3.85	5.31	7.38	8.87	8.97
Quick Ratio	1.72	2.24	2.17	3.60	4.46	4.04
Current Ratio	2.34	2.90	2.69	3.99	4.83	4.46
Return on Equity (ROE)	20.80%	22.54%	-3.15%	22.99%	27.67%	24.93%
Return on Assets (ROA)	10.62%	12.16%	12.14%	13.17%	17.33%	19.32%
Return on Invested Capital (ROIC)	23.07%	30.54%	-98.60%	63.54%	90.72%	102.53%
Return on Capital Employed (ROCE)	17.60%	21.50%	23.20%	22.50%	28.40%	34.50%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	2.84%	3.44%	-0.52%	3.45%	4.48%	4.20%
FCF Yield	2.31%	2.78%	-0.76%	3.18%	5.29%	4.31%
Buyback Yield / Dilution	1.01%	-0.04%	1.00%	-0.54%	0.31%	1.33%

SEC Filings: 10-K · 10-Q